Premium
L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Preliminary Results
Author(s) -
Burke William J.,
Ranno Anthony E.,
Roccaforte William H.,
Wengel Steven P.,
Bayer Barbara L.,
Willcockson Nancy K.
Publication year - 1993
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.1993.tb06942.x
Subject(s) - medicine , neuropsychology , placebo , dementia , clinical dementia rating , clinical trial , randomized controlled trial , selegiline , cognition , alzheimer's disease , rating scale , psychiatry , psychology , disease , developmental psychology , parkinson's disease , pathology , alternative medicine
Objective : To examine the short‐term cognitive and behavioral effects of L‐deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 2‐month period. Design : A 15‐month randomized, double‐blind, placebo‐controlled trial using a parallel‐group design. This report deals with the first 2 months of the trial. Participants : 39 subjects with mild DAT (CDR 1) selected using NINCDS‐ADRDA criteria. Measures : A battery of neuropsychological tests and clinical rating scales. Results : The placebo and L‐deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. There was no evidence of a L‐deprenyl effect on any clinical or neuropsychological measures after 2 months. Conclusion : L‐deprenyl did not have a measurable impact on behavior or cognitive function over a 2‐month period in this group of subjects with mild DAT.